Seksan Mongkhonkhamsao/Getty Images
Over the course of the last 15 years, the discovery that some lung cancers are driven by gene mutations that can be targeted with drugs has dramatically increased survival time for many patients. However, one identified mutation, to the KRAS gene, has eluded effective drugs.
Data from a phase 2 trial presented at the conference showed that, of 126 patients with non-small-cell lung cancer and a KRAS mutation treated with the experimental cancer drug sotorasib, 37.1 percent responded.
The average progression-free survival for all patients in the trial (the length of time in which the tumor did not grow) was 6.8 months. For patients who responded to the drug, the duration of the response lasted on average for 10 months.
Nivolumab Found Effective to Treat Malignant Mesothelioma by Angela Mohan on February 1, 2021 at 12:18 PM
Nivolumab found effective for relapsed malignant mesothelioma (MM), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Malignant mesothelioma is an intractable cancer, and no phase III trial has yet shown an improvement in overall survival following the standard first line chemotherapy doublet comprising pemetrexed and cisplatin or carboplatin since it was licensed in 2004.
Professor Dean Fennell, chair of Thoracic Medical Oncology at the University of Leicester in collaboration with Professor Gareth Griffiths and his team at the Southampton Clinical Trials Unit, University of Southampton, UK, presented results of the Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study, funded by Cancer Research UK/Stand Up To Cancer.
Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer
A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Lung cancer researchers and clinicians have sought methods to improve chemotherapy s modest 5% overall survival rate for patients with NSCLC. Dr. Silvia Novello, professor of medical oncology at the University of Torino at San Luigi Gonzaga Hospital, Orbassano, Italy, and a large group of European researchers evaluated the predictive utility of the mRNA expression levels of molecular markers, mRNA expression levels of molecular markers, excision repair cross-complementing group ERCC1 and th
E-Mail
(Singapore January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST) A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Lung cancer researchers and clinicians have sought methods to improve chemotherapy s modest 5% overall survival rate for patients with NSCLC. Dr. Silvia Novello, professor of medical oncology at the University of Torino at San Luigi Gonzaga Hospital, Orbassano, Italy, and a large group of European researchers evaluated the predictive utility of the mRNA expression levels of molecular markers, mRNA expression levels of molecular markers, excision repair cross-complementing group ERCC1 and thymidylate syntha
E-Mail
(Singapore January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST) Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Malignant mesothelioma is an intractable cancer, and no phase III trial has yet shown an improvement in overall survival following the standard first line chemotherapy doublet comprising pemetrexed and cisplatin or carboplatin since it was licensed in 2004.
Professor Dean Fennell, chair of Thoracic Medical Oncology at the University of Leicester in collaboration with Professor Gareth Griffiths and his team at the Southampton Clinical Trials Unit, University of Southampton, UK, presented results of the Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study, funded by Cancer Research UK/Stand Up To Cancer. The investigator-led, placebo-controlled rando